Literature DB >> 29599089

Cancer-salient messaging for Human Papillomavirus vaccine uptake: A randomized controlled trial.

Rachael M Porter1, Avnika B Amin2, Robert A Bednarczyk3, Saad B Omer4.   

Abstract

BACKGROUND AND OBJECTIVES: Vaccination with Human Papillomavirus (HPV) vaccine is recommended for 11-12 years-old, but uptake is suboptimal. Current messaging focuses on HPV infection transmission and prevention. Parents and providers are often uncomfortable discussing sexual practices of adolescents, contributing to the delay/refusal of vaccine. We created a cervical cancer-salient message encouraging HPV vaccination, emphasizing disease salience and disease threat, while promoting self-efficacy. We hypothesized this message would have greater effects on vaccine confidence and intent to vaccinate compared to Centers for Disease Control and Prevention (CDC) and non-vaccine control messages.
METHODS: A 3-arm randomized trial was conducted. Parents of girls aged 9-17 were eligible for the study. We measured participants' vaccine confidence and intent to vaccinate at baseline and post intervention message. Recruitment and surveys were administered online through Amazon Mechanical Turk.
RESULTS: 762 participants completed both surveys. We saw modest increases in vaccine confidence when comparing cervical cancer arm and control arm, and CDC arm and control arm; estimates were not statistically significant. The odds of reporting intent to vaccinate among the cervical cancer message arm were 1.13 times the odds of reporting intent to vaccinate in the control arm (95% CI: 0.30. 4.29). Intent to vaccinate was also not statistically significantly different between CDC message arm and control arm (OR = 1.25, 95%CI: 0.66, 2.37).
CONCLUSION: Neither message had effect on intent to vaccinate, highlighting need for research to identify successful messaging strategies for HPV. Exploratory analyses suggest among parents with 'Low' vaccine confidence at baseline, the cervical cancer framed message may be more effective in changing intention than the CDC message or non-vaccine control. Future work should target groups with 'Low' or 'Medium' vaccine confidence at baseline - they may be more amenable to change, and more receptive to disease-salient messaging. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov, Reference #: NCT03002324.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29599089      PMCID: PMC6550298          DOI: 10.1016/j.vaccine.2018.01.040

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Questions and Concerns About HPV Vaccine: A Communication Experiment.

Authors:  Parth D Shah; William A Calo; Melissa B Gilkey; Marcella H Boynton; Susan Alton Dailey; Karen G Todd; Meagan O Robichaud; Marjorie A Margolis; Noel T Brewer
Journal:  Pediatrics       Date:  2019-01-22       Impact factor: 7.124

2.  Association of cognitive biases with human papillomavirus vaccine hesitancy: a cross-sectional study.

Authors:  Tiffany D Pomares; Alison M Buttenheim; Avnika B Amin; Caroline M Joyce; Rachael M Porter; Robert A Bednarczyk; Saad B Omer
Journal:  Hum Vaccin Immunother       Date:  2019-12-20       Impact factor: 3.452

3.  The interdependent roles of the psychosocial predictors of human papillomavirus vaccination among Christian parents of unvaccinated adolescents.

Authors:  Ayokunle Olagoke; Rachel Caskey; Brenikki Floyd; Jennifer Hebert-Beirne; Andrew Boyd; Yamilé Molina
Journal:  Hum Vaccin Immunother       Date:  2021-12-02       Impact factor: 3.452

4.  The effect of education based on the theory of planned behavior on the intention of vaccination against human papillomavirus in female students: A controlled educational trial.

Authors:  Golchehreh Zomordi; Maryam Moradi; Malihe Hasanzadeh; Vahid Ghavami
Journal:  J Educ Health Promot       Date:  2022-07-29

5.  A Tale of Two Diverse Qualtrics Samples: Information for Online Survey Researchers.

Authors:  Carrie A Miller; Jeanine P D Guidry; Bassam Dahman; Maria D Thomson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-02-17       Impact factor: 4.254

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.